20 / 21
Page 66
allied
academies
Microbiology: Current Research 2017 | Volume 1, Issue 2
Joint Conference
GLOBAL APPLIED MICROBIOLOGY CONFERENCE
MICROBIAL & BIOCHEMICAL RESEARCH AND TECHNOLOGIES
October 18-19, 2017
Toronto, Canada
International Congress on
&
Introduction:
Hepatitis C is an infectious disease affecting
primarily the liver, caused by the hepatitis C virus (HCV). HCV
infection is a major problem in Egypt. Egypt has the highest
prevalence of the Hepatitis C virus (HCV) in the world, with
14 percent of the population infected and 11.8 million
patients, according to the World Health Organization. Every
year there are 170,000-200,000 new HVC cases in Egypt.
It was first discovered in 1989. The hepatitis C virus (HCV)
is a small, enveloped, single-stranded, positive-sense RNA
virus. It is a member of the
Hepacivirus
genus in the family
Flaviviridae
. There are seven major genotypes of HCV, which
are known as genotypes one to seven. It is transmitted by
injection, which means spread primarily by blood-to-blood
contact associated with intravenous drug use, poorly-
sterilized medical equipment, and transfusions.
Aim of the study:
This study aims to determine the common
prevalent HCV genotypes among chronic HCV patients
in Egypt and to evaluate the rate of sustained virological
response (SVR) with some factors that affecting it.
Subject & Methods:
In our study, fifty patients were
enrolled. Eligible participants were aged ≥18 years, had
chronic HCV genotype 4 infection (serum HCV RNA≥2000 IU/
mL). All Biochemical tests for liver function, Blood sugar and
HBA1C were done for all cases. The recommended regimen
was DCV 60 mg plus SOF 400 mg once daily for 12 weeks;
at their discretion, physicians could add RBV to the regimen
or reduce treatment duration. HCV-RNA (viral load) was
measured using RT-PCR (quantitative method) (Qiagen/BD
Company) (Before treatment and after 12 weeks).
Results:
SVR achieved 12 weeks after the end of treatment.
Of the 50 evaluable patients, six received DCV+SOF and
44 DCV+SOF+RBV. Most patients were men (76%). SVR12
(modified intention-to-treat) was achieved by 98%of patients
(48/50); one patient had virological breakthrough (was lost
to follow-up at four weeks after treatment) and one patients
relapsed. There was no statistically significant difference in
treatment efficacy between treatment-naive patients (100%,
37 of 37) and those with treatment experience (84.6%; 11
of 13) (P=51). High SVR12 was observed regardless cirrhosis
and level of diabetes.
Conclusions:
In our study, the most predominant genotype
was genotype IV with 86%. Of our HCV-treated patients, had
high SVR. HCV genotype-4, and low baseline viral load were
predictive of SVR.
e:
refat.sadek@med.psu.edu.egViral load predicts virological response to therapy in chronic hepatitis C
Sadeq R
1
, Rabie R
1
and
Shafik N
2
1
Portsaid University, Egypt
2
WHO, Switzerland